Xenon Pharmaceuticals Inc (XENE.OQ)
17 Aug 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|71||Chairman of the Board|
|42||2018||President, Chief Financial Officer, Chief Operating Officer|
|48||2018||Chief Executive Officer, Director|
|2016||Senior Vice President - Drug Discovery|
|54||2012||Senior Vice President of Business and Corporate Development|
- BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference
- BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21
- BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co
- BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results
- BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement